Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18563435 | 0.88 | — | — | |
| SCHEMBL18638588 | 0.83 | LMNA (0.30) | TSHR | |
| SCHEMBL597785 | 0.81 | — | — | |
| SCHEMBL18124685 | 0.80 | TSHR (0.32) | TSHR | |
| SCHEMBL1645582 | 0.78 | — | — | |
| SCHEMBL10496939 | 0.78 | — | — | |
| SCHEMBL12325604 | 0.78 | TSHR (0.32) | TSHR | |
| SCHEMBL25922198 | 0.78 | — | — | |
| SCHEMBL11039052 | 0.78 | TSHR (0.32) | TSHR | |
| SCHEMBL831126 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2829555-B1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-05-16 | — | — | EP | claimed |
| CN-104203993-B | Process for producing olefin polymer | 三井化学株式会社 | 2016-06-15 | — | — | CN | claimed |
| US-9315602-B2 | Method for producing olefin polymer | MITSUI CHEMICALS, INC. (JP) | 2016-04-19 | — | — | US | claimed |
| US-12616728-B2 | Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same | SUPER CRITICAL IP, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250152646-A1 | SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING CANNABINOIDS FROM PLANTS EXTRACTS OR FROM SYNTHETIC PATHWAYS | NOEL ARMAND J (US) | 2025-05-15 | — | — | US | disclosed |
| US-12090185-B2 | Processes for converting cannabinoids into cannabinoid derivatives and recovering the same | SUPER CRITICAL IP, LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240082335-A1 | PROCESSES AND SYSTEMS FOR CONVERTING CANNABINOIDS INTO CANNABINOID DERIVATIVES AND ISOLATING THE SAME | SUPER CRITICAL IP, LLC | 2024-03-14 | — | — | US | disclosed |
| US-11872259-B2 | Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same | SUPER CRITICAL IP, LLC (US) | 2024-01-16 | — | — | US | disclosed |
| US-11759491-B2 | Solvents, methods, and systems for isolating botanical extracts from plants | SUPER CRITICAL IP, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230032750-A1 | PROCESSES FOR CONVERTING CANNABINOIDS INTO CANNABINOID DERIVATIVES AND RECOVERING THE SAME | SUPER CRITICAL IP, LLC | 2023-02-02 | — | — | US | disclosed |
| US-20230036925-A1 | SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING BOTANICAL EXTRACTS FROM PLANTS | SUPER CRITICAL IP, LLC | 2023-02-02 | — | — | US | disclosed |
| CN-1620295-A | Preparation of intermediates for the synthesis of antiviral nucleosides | PHARMASSET LTD (BB) | 2005-05-25 | — | — | CN | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| US-5015799-A | Oxidative coupling process for converting methane and/or natural gas to more transportable products | AMOCO CORPORATION (US) | 1991-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616728-B2 | Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same | CNR2, CNR1, SCD | TSHR 2794/4885TDP1 4427/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | TSHR 4374/4885TDP1 1215/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | TSHR 4420/4885TDP1 2045/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | TSHR 3766/4885TDP1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.